GLP-1 activation slows down gastric emptying, which means food stays in your stomach longer than usual
Because great skin isnt about shortcutsits about the right science, done right
#EliLilly #Retatrutide #GLP1 #GIP #Glucagon #ObesityTreatment #Phase3 #TRIUMPH1 #WeightLossDrugs Eli Lillys retatrutide, a GIP/GLP-1/glucagon triple agonist, met Phase 3 endpoints, delivering 28.3% weight loss over 80 weeks in TRIUMPH-1
The TGAs expansion follows a 2024 clinical trial which found semaglutide reduces the risk of major kidney events in type 2 diabetes patients by 24%
Will I be able to communicate with a provider
In summary, the findings so far discussed point each other to the role of androgen/AR pathway impairment in skeletal muscle wasting, sarcopenia progression, obesity, insulin-resistance, inflammation and immuno-senescence